Management struck an upbeat tone, emphasizing raised guidance, strong execution, and reiterated margin-recovery targets while framing regulatory changes as manageable.
Вывод BuzzbergRaises 2026 EPS guidance to $7.30-$7.50Management struck an upbeat tone, emphasizing raised guidance, strong execution, and reiterated margin-recovery targets while framing regulatory changes as manageable.Читать полный анализСвернуть анализ
Management struck an upbeat tone, emphasizing raised guidance, strong execution, and reiterated margin-recovery targets while framing regulatory changes as manageable.
Revenue$100.426B
-5% QoQ
EPS$2.31
reported
Gross margin15.56%
reported
Op margin4.66%
reported
Что изменилось в этом квартале
01
Guidance
Raises 2026 EPS guidance to $7.30-$7.50
Guidance tone
02
Medicare Advantage
CMS rate notice still insufficient for medical trends
03
AI
Plans AI-native Health 100 launch later this year
Management framed AI as an inflection point and a core strategic enabler, not just a cost tool. They expect the upcoming Health 100 AI-native platform to connect payers, PBMs, pharmacies, and providers, while also deploying AI to improve member navigation, prior authorization…
04
Pharmacy
Expects biosimilar switch to drive zero copay outcomes
AI, капзатраты и спрос
AI
Платформа и монетизация
Management framed AI as an inflection point and a core strategic enabler, not just a cost tool. They expect the upcoming Health 100 AI-native platform to connect payers, PBMs, pharmacies, and providers, while also deploying AI to improve member navigation, prior authorization speed, and consumer engagement. No AI-specific revenue or ROI metrics were provided.
Спрос
Заказы и конверсия
Management raised full-year 2026 adjusted EPS guidance following a strong Q1, driven by margin recovery at Aetna and the pharmacy businesses.
Капзатраты
Инвестиции и мощности
No explicit capex or dollar figures were given. Management indicated continued investment in technology and AI infrastructure, including the Health 100 platform and an internal AI Academy, positioning these as deliberate reinvestments to differentiate the company rather than as near-term earnings drags.
Тон · Confident
Management struck an upbeat tone, emphasizing raised guidance, strong execution, and reiterated margin-recovery targets while framing regulatory changes as manageable.
Альфа цепочки поставок
A1
Aetna's medical benefit ratio of 84.6% was better than expected due to favorable prior year development, but management chose not to bake any of the current-year core outperformance into the full-year outlook, maintaining a cautious stance on medical cost trends.
“we did see some pockets of core outperformance, and that was driven by strong medical cost management, which has not been reflected in our updated guidance”
CVS's Health Services segment pulled forward value from Q2 into Q1, masking some of the underlying rebate guarantee pressure, though the underlying business still modestly beat expectations.
CVS expects standardized prior authorizations to cover over 50% of volume across the industry by end of 2026, with Aetna already at 88% standardization.
“over 50% of the PA volume by the end of this year. Importantly, Aetna is well ahead of the industry standard with 88% of procedures standardized today.”
Yeah. Good morning, guys. And thanks for taking the question. I kind of wanted to come back to pharmacy and the GLP-1 market. And I guess I wanted to ask, again, a multi-partner, like how focused are you guys on retaining share in that space? How has the margin profile progressed in that space given the move up to the cost plus model? And related to the cost plus model, at the start of this quarter, we saw the prices of a bunch of drugs come down because of IRA or MFN. Historically, they might have been money losing drugs for the pharmacy side of the business, but as the spreads narrow, as the prices come down, I'd just be interested in understanding how the margin profile is evolving.…
Ответ менеджмента
David JoynerChair and Chief Executive Officer at CVS Health
Thank you. Yeah, thanks, George. I'll take the first part and let Prem talk a little bit about some of the impacts on retail. This remains probably the most talked about category, whether it be among consumers and or payers. So to all the things we've said earlier, as a PBM and as a payer, we're very much focused on managing the cost of this category, which is why we've introduced competition in the formulary, which is why we're wrapping around a robust set of weight management solutions today. on the category. So it is important to us for a whole host of reasons because we've got to deliver value for our customers to show and demonstrate that we're having a meaningful impact on the overall health status of their population and ultimately making sure that we're driving an affordable solution on the pharmacy side. As Prem mentioned earlier, we still have a lot of clients that are actually discontinuing coverage for the obesity products of GLP-1s. And This is where when you ask the question, how important is it? I think we actually have one of the most robust and or holistic solutions to GLP-1s because we've built an extensive and compelling direct-to-consumer solution for patients in the GLP-1 category, whether it be our partnerships with the Novocare and or just in general, as you're seeing the shift from on-benefit to off-benefit, CVS Pharmacy remains a very viable solution and distribution channel for the category. So And to your to your point, where it was a headwind several years ago, our migration to the cost advantage price model has neutralized that. So while we're not losing money, we're not we're not over earning on the category either. But ultimately, it allows us to basically participate on every drug. fair and value-based approach that creates that. So maybe you want to just speak a little bit to the basis point growth that we've seen?
Aetna's medical benefit ratio of 84.6% was better than expected due to favorable prior year development, but management chose not to bake any of the current-year core outperformance into the full-year outlook, maintaining a cautious stance on medical cost trends. — Suggests either a future earnings beat if cost trends stay favorable or a prudent conservatism; implies sector-wide medical cost pressure persists.
CVS's Health Services segment pulled forward value from Q2 into Q1, masking some of the underlying rebate guarantee pressure, though the underlying business still modestly beat expectations. — Indicates timing dynamics within PBM earnings and the ongoing financial impact of rebate reform and transparency agreements.
… 11% year over year. This increase was primarily driven by pharmacy drug mix and brand inflation, partially offset by continued pharmacy client price improvements. We delivered adjusted operating income of approximately $1.5 billion in the quarter. a decrease of approximately 7% from the prior year quarter, primarily driven by continued pharmacy client price improvements, partially offset by improved purchasing economics and pharmacy drug mix. Our results this quarter also reflect the early recognition of value that we previously expected to occur in the second quarter. When excluding the impact of this pull forward, our health services segment still modestly exceeded our previous expectations. We are encouraged by progress in our healthcare delivery business during the quarter, which delivered results that were broadly in line with our expectations. Total revenues grew over 15% compared to the same quarter last year, primarily driven by Oak Street Health. Our pharmacy and consumer wellness segment delivered another strong quarter. We generated revenues of nearly $32 billion, which remained relatively consistent with the prior year quarter. In the quarter, we saw increases …
CVS expects standardized prior authorizations to cover over 50% of volume across the industry by end of 2026, with Aetna already at 88% standardization.
David JoynerChair and Chief Executive Officer at CVS Health
… time. We've integrated medical and pharmacy decisions, and we've introduced bundling solutions for certain conditions that replaced multiple approvals with just one. And now we're leading the way forward by standardizing prior authorization submissions. Over the past several months, we rallied and worked with key industry peers through AHIP to commit to standardize the services for the most common prior authorizations, which represent over 50% of the PA volume by the end of this year. Importantly, Aetna is well ahead of the industry standard with 88% of procedures standardized today. This is a meaningful step towards faster decisions, less administrative burden, and a better experience for clinicians and patients alike. As we look ahead, the next critical step is ensuring other stakeholders within the healthcare system open up their own systems so these standards can be fully adopted and the benefits of this work can be realized at scale. While we drive towards reducing cost and friction in the system, Our work to reimagine the healthcare experience is also directly aligned with our priorities around access and interoperability. At our Investor Day in December, we outlined our …
Cookie
Мы используем cookie для работы сайта и аналитики. Если вы откажетесь, доступ к контенту не изменится.